US OptionsDetailed Quotes
ASRT250117C1500
- 0.05
- 0.000.00%
15min DelayClose Jan 3 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume1.24K Open Interest1.50Strike Price0.00Turnover270.56%IV75.34%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2323Delta0.6528Gamma17.69Leverage Ratio-0.0051Theta0.0001Rho4.11Eff Leverage0.0005Vega
Assertio Stock Discussion
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
Friday, 13th December at 8:00 am
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon® (eflapegrastim-x...
Underated/Valued, overlooked, great buy!!!
This one is killin it....
No comment yet